Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002513208 | SCV003442363 | pathogenic | Spastic paraplegia | 2022-04-09 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr170*) in the FA2H gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FA2H are known to be pathogenic (PMID: 20853438, 25496456, 25732363, 26344562). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 30873). This variant is also known as c.509_510delAC. This premature translational stop signal has been observed in individual(s) with clinical features of FA2H-related conditions (PMID: 20853438, 23745665, 31135052). This variant is not present in population databases (gnomAD no frequency). |
Gene |
RCV004700275 | SCV005201362 | pathogenic | not provided | 2024-01-09 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 23745665, 20853438, 31135052) |
Mayo Clinic Laboratories, |
RCV004700275 | SCV005414355 | pathogenic | not provided | 2024-01-31 | criteria provided, single submitter | clinical testing | PP1, PM2, PM3, PVS1 |
OMIM | RCV000023858 | SCV000045149 | pathogenic | Hereditary spastic paraplegia 35 | 2014-04-01 | no assertion criteria provided | literature only |